2021-2027 Global and Regional Radiopharmaceuticals in Nuclear Medicine Industry Status and Prospects Professional Market Research Report Standard Version
Date: Dec-2021 | Id: MACRC-73236 | Geographical Scope: Global | Publisher: Mnemonics Research
The global Radiopharmaceuticals in Nuclear Medicine market was valued at 4833.21 Million USD in 2020 and will grow with a CAGR of 5.18% from 2020 to 2027, based on Mnemonics Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America). By Market Verdors: Bracco Imaging S.P.A. Cambridge Isotope Laboratories, Inc. Cardinal Health, Inc. Covidien, Plc Eczacibasi-Monrol Fujifilm Holdings Corporation GE Healthcare (Subsidiary Of General Electric Company) IBA Group Isotec, Inc. (Sigma-Aldrich) Lantheus Medical Imaging, Inc. Nordion, Inc. Ntp Radioisotopes (Pty), Ltd. Siemens Healthcare (Subsidiary Of Siemens AG) Taiyo Nippon Sanso Corporation Urenco Limited Rotem Industries, Ltd., Inc. Australian Nuclear Association And Technology Organization (ANSTO) Board of Radiation And Isotope Technology (BRIT) Institute of Atomic Energy Polatom Radioisotope Centre Institute of Isotopes Co., Ltd. Institute Of Radioelement (IRE) By Types: Diagnostic Radiopharmaceuticals Therapy Radiopharmaceuticals Enriched Stable Isotopes By Applications: Diagnostic Application Therapeutic Application Research Pharmaceutical Key Indicators Analysed Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors. Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications. Market Trends: Market key trends which include Increased Competition and Continuous Innovations. Opportunities and <b>Drivers:</b> Identifying the Growing Demands and New Technology Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry. Key Reasons to Purchase To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape. Assess the production processes, major issues, and solutions to mitigate the development risk. To understand the most affecting driving and restraining forces in the market and its impact in the global market. Learn about the market strategies that are being adopted by leading respective organizations. To understand the future outlook and prospects for the market. Besides the standard structure reports, we also provide custom research according to specific requirements.
Chapter 1 Industry Overview 1.1 Definition 1.2 Assumptions 1.3 Research Scope 1.4 Market Analysis by Regions 1.4.1 North America Market States and Outlook (2022-2027) 1.4.2 East Asia Market States and Outlook (2022-2027) 1.4.3 Europe Market States and Outlook (2022-2027) 1.4.4 South Asia Market States and Outlook (2022-2027) 1.4.5 Southeast Asia Market States and Outlook (2022-2027) 1.4.6 Middle East Market States and Outlook (2022-2027) 1.4.7 Africa Market States and Outlook (2022-2027) 1.4.8 Oceania Market States and Outlook (2022-2027) 1.4.9 South America Market States and Outlook (2022-2027) 1.5 Global Radiopharmaceuticals in Nuclear Medicine Market Size Analysis from 2022 to 2027 1.5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Analysis from 2022 to 2027 by Consumption Volume 1.5.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size Analysis from 2022 to 2027 by Value 1.5.3 Global Radiopharmaceuticals in Nuclear Medicine Price Trends Analysis from 2022 to 2027 1.6 COVID-19 Outbreak: Radiopharmaceuticals in Nuclear Medicine Industry Impact Chapter 2 Global Radiopharmaceuticals in Nuclear Medicine Competition by Types, Applications, and Top Regions and Countries 2.1 Global Radiopharmaceuticals in Nuclear Medicine (Volume and Value) by Type 2.1.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption and Market Share by Type (2016-2021) 2.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue and Market Share by Type (2016-2021) 2.2 Global Radiopharmaceuticals in Nuclear Medicine (Volume and Value) by Application 2.2.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption and Market Share by Application (2016-2021) 2.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue and Market Share by Application (2016-2021) 2.3 Global Radiopharmaceuticals in Nuclear Medicine (Volume and Value) by Regions 2.3.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption and Market Share by Regions (2016-2021) 2.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue and Market Share by Regions (2016-2021) Chapter 3 Production Market Analysis 3.1 Global Production Market Analysis 3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis 3.1.2 2016-2021 Major Manufacturers Performance and Market Share 3.2 Regional Production Market Analysis 3.2.1 2016-2021 Regional Market Performance and Market Share 3.2.2 North America Market 3.2.3 East Asia Market 3.2.4 Europe Market 3.2.5 South Asia Market 3.2.6 Southeast Asia Market 3.2.7 Middle East Market 3.2.8 Africa Market 3.2.9 Oceania Market 3.2.10 South America Market 3.2.11 Rest of the World Market Chapter 4 Global Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import by Regions (2016-2021) 4.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption by Regions (2016-2021) 4.2 North America Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021) 4.3 East Asia Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021) 4.4 Europe Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021) 4.5 South Asia Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021) 4.6 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021) 4.7 Middle East Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021) 4.8 Africa Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021) 4.9 Oceania Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021) 4.10 South America Radiopharmaceuticals in Nuclear Medicine Sales, Consumption, Export, Import (2016-2021) Chapter 5 North America Radiopharmaceuticals in Nuclear Medicine Market Analysis 5.1 North America Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis 5.1.1 North America Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19 5.2 North America Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types 5.3 North America Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application 5.4 North America Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries 5.4.1 United States Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 5.4.2 Canada Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 5.4.3 Mexico Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 Chapter 6 East Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis 6.1 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis 6.1.1 East Asia Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19 6.2 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types 6.3 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application 6.4 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries 6.4.1 China Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 6.4.2 Japan Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 6.4.3 South Korea Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 Chapter 7 Europe Radiopharmaceuticals in Nuclear Medicine Market Analysis 7.1 Europe Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis 7.1.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19 7.2 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types 7.3 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application 7.4 Europe Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries 7.4.1 Germany Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 7.4.2 UK Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 7.4.3 France Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 7.4.4 Italy Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 7.4.5 Russia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 7.4.6 Spain Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 7.4.7 Netherlands Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 7.4.8 Switzerland Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 7.4.9 Poland Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 Chapter 8 South Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis 8.1 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis 8.1.1 South Asia Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19 8.2 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types 8.3 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application 8.4 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries 8.4.1 India Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 8.4.2 Pakistan Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 8.4.3 Bangladesh Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 Chapter 9 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis 9.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis 9.1.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19 9.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types 9.3 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application 9.4 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries 9.4.1 Indonesia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 9.4.2 Thailand Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 9.4.3 Singapore Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 9.4.4 Malaysia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 9.4.5 Philippines Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 9.4.6 Vietnam Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 9.4.7 Myanmar Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 Chapter 10 Middle East Radiopharmaceuticals in Nuclear Medicine Market Analysis 10.1 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis 10.1.1 Middle East Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19 10.2 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types 10.3 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application 10.4 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries 10.4.1 Turkey Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 10.4.2 Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 10.4.3 Iran Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 10.4.4 United Arab Emirates Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 10.4.5 Israel Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 10.4.6 Iraq Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 10.4.7 Qatar Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 10.4.8 Kuwait Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 10.4.9 Oman Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 Chapter 11 Africa Radiopharmaceuticals in Nuclear Medicine Market Analysis 11.1 Africa Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis 11.1.1 Africa Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19 11.2 Africa Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types 11.3 Africa Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application 11.4 Africa Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries 11.4.1 Nigeria Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 11.4.2 South Africa Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 11.4.3 Egypt Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 11.4.4 Algeria Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 11.4.5 Morocco Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 Chapter 12 Oceania Radiopharmaceuticals in Nuclear Medicine Market Analysis 12.1 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis 12.2 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types 12.3 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application 12.4 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption by Top Countries 12.4.1 Australia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 12.4.2 New Zealand Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 Chapter 13 South America Radiopharmaceuticals in Nuclear Medicine Market Analysis 13.1 South America Radiopharmaceuticals in Nuclear Medicine Consumption and Value Analysis 13.1.1 South America Radiopharmaceuticals in Nuclear Medicine Market Under COVID-19 13.2 South America Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Types 13.3 South America Radiopharmaceuticals in Nuclear Medicine Consumption Structure by Application 13.4 South America Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Major Countries 13.4.1 Brazil Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 13.4.2 Argentina Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 13.4.3 Columbia Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 13.4.4 Chile Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 13.4.5 Venezuela Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 13.4.6 Peru Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 13.4.7 Puerto Rico Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 13.4.8 Ecuador Radiopharmaceuticals in Nuclear Medicine Consumption Volume from 2016 to 2021 Chapter 14 Company Profiles and Key Figures in Radiopharmaceuticals in Nuclear Medicine Business 14.1 Bracco Imaging S.P.A. 14.1.1 Bracco Imaging S.P.A. Company Profile 14.1.2 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Specification 14.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.2 Cambridge Isotope Laboratories, Inc. 14.2.1 Cambridge Isotope Laboratories, Inc. Company Profile 14.2.2 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification 14.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.3 Cardinal Health, Inc. 14.3.1 Cardinal Health, Inc. Company Profile 14.3.2 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification 14.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.4 Covidien, Plc 14.4.1 Covidien, Plc Company Profile 14.4.2 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Specification 14.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.5 Eczacibasi-Monrol 14.5.1 Eczacibasi-Monrol Company Profile 14.5.2 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Specification 14.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.6 Fujifilm Holdings Corporation 14.6.1 Fujifilm Holdings Corporation Company Profile 14.6.2 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification 14.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.7 GE Healthcare (Subsidiary Of General Electric Company) 14.7.1 GE Healthcare (Subsidiary Of General Electric Company) Company Profile 14.7.2 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Specification 14.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.8 IBA Group 14.8.1 IBA Group Company Profile 14.8.2 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Specification 14.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.9 Isotec, Inc. (Sigma-Aldrich) 14.9.1 Isotec, Inc. (Sigma-Aldrich) Company Profile 14.9.2 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Specification 14.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.10 Lantheus Medical Imaging, Inc. 14.10.1 Lantheus Medical Imaging, Inc. Company Profile 14.10.2 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification 14.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.11 Nordion, Inc. 14.11.1 Nordion, Inc. Company Profile 14.11.2 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification 14.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.12 Ntp Radioisotopes (Pty), Ltd. 14.12.1 Ntp Radioisotopes (Pty), Ltd. Company Profile 14.12.2 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification 14.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.13 Siemens Healthcare (Subsidiary Of Siemens AG) 14.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Company Profile 14.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Specification 14.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.14 Taiyo Nippon Sanso Corporation 14.14.1 Taiyo Nippon Sanso Corporation Company Profile 14.14.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification 14.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.15 Urenco Limited 14.15.1 Urenco Limited Company Profile 14.15.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Specification 14.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.16 Rotem Industries, Ltd., Inc. 14.16.1 Rotem Industries, Ltd., Inc. Company Profile 14.16.2 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification 14.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.17 Australian Nuclear Association And Technology Organization (ANSTO) 14.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Company Profile 14.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Specification 14.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.18 Board of Radiation And Isotope Technology (BRIT) 14.18.1 Board of Radiation And Isotope Technology (BRIT) Company Profile 14.18.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Specification 14.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.19 Institute of Atomic Energy Polatom Radioisotope Centre 14.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Company Profile 14.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Specification 14.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.20 Institute of Isotopes Co., Ltd. 14.20.1 Institute of Isotopes Co., Ltd. Company Profile 14.20.2 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification 14.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.21 Institute Of Radioelement (IRE) 14.21.1 Institute Of Radioelement (IRE) Company Profile 14.21.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Specification 14.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021) Chapter 15 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast (2022-2027) 15.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Price Forecast (2022-2027) 15.1.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume and Growth Rate Forecast (2022-2027) 15.1.2 Global Radiopharmaceuticals in Nuclear Medicine Value and Growth Rate Forecast (2022-2027) 15.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027) 15.2.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume and Growth Rate Forecast by Regions (2022-2027) 15.2.2 Global Radiopharmaceuticals in Nuclear Medicine Value and Growth Rate Forecast by Regions (2022-2027) 15.2.3 North America Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.4 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.5 Europe Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.6 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.7 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.8 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.9 Africa Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.10 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.11 South America Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.3 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume, Revenue and Price Forecast by Type (2022-2027) 15.3.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Forecast by Type (2022-2027) 15.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Type (2022-2027) 15.3.3 Global Radiopharmaceuticals in Nuclear Medicine Price Forecast by Type (2022-2027) 15.4 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume Forecast by Application (2022-2027) 15.5 Radiopharmaceuticals in Nuclear Medicine Market Forecast Under COVID-19 Chapter 16 Conclusions Research Methodology
Related reports
Non-Hodgkin Lymphoma Therapeutics Market
$2000-$6000
Acrylic Teeth Market
$3600-$7000